In response to the global burden of severe RSV disease among infants, WHO recommends that all countries introduce either the ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections in infants ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

A single injection of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) ...

Nirsevimab implementation in Catalonia, Spain, reduced emergency department visits and hospital admissions for bronchiolitis ...

Discover a study that highlights the importance of identifying high-risk children through biomarkers and better understanding ...

RSV leads to over 100,000 infant deaths annually, but WHO’s latest guidance recommends maternal vaccines and monoclonal ...

RSV infections in children needing primary care cause high economic impact due to outpatient costs and parental work absences ...

Infections from respiratory syncytial virus (RSV) in children requiring primary care led to significant societal economic costs from outpatient treatment and parental work absences in Europe, ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...